CRE Alzheimer
Salamanca

• Publicaciones
• Publicaciones, Artículos

Susana I. Justo Henriques, Enrique Pérez Sáez y João L. Alves Apóstolo

• Enlace al documento

• Demencias
• Terapias no farmacológicas
• Reminiscencia

Objectives: To evaluate the effectiveness of a 13-week individual Reminiscence Therapy intervention to improve the overall cognitive function, memory, executive function, mood, and quality of life of people with neurocognitive disorders.

Methods: A single-blind, multicentre, randomised parallel two-arm controlled trial recruited 251 people with neurocognitive disorders attending 24 institutions providing care and support services for older adults in Portugal. The primary outcome measure was cognitive function (MMSE). Secondary outcomes were memory (MAT), executive function (FAB), mood (GDS-15), and self-reported quality of life (QoL-AD). Participants in the intervention group (n= 131) received 26 individual Reminiscence therapy sessions, twice a week, over the course of 13 weeks. Participants in the control group (n= 120) maintained their treatment as usual.

Results: Intention-to-treat analysis showed that, at endpoint assessment, the intervention group had significantly improved in relation to the control group in MMSE (mean difference 1.84, 95% CI [0.80, 2.89], p = .001, d = .44), MAT (mean difference 2.82, 95% CI [0.72, 4.91], p = .009, d = .34), and QoL-AD (mean difference 1.78, 95% CI [0.17, 3.39], p = .031, d = .28). Non-significant improvements were found on FAB (mean difference 0.74, 95% CI [-0.04, 1.52], p = .062, d = .24) and GDS-15 (mean difference -0.63, 95% CI [-1.45, 0.19], p =.130, d = .19).

Conclusions: For people with neurocognitive disorders attending social care and support services, the individual Reminiscence Therapy designed for this trial should be considered an intervention with the potential to improve cognition, memory, and quality of life.